Pharmacy middlemen are working on a proposal to voluntarily change some of their business practices in an effort to avoid new regulation from the Trump administration, according to sources https://t.co/jLXcZBgMBA ...

Cuban said drug prices are opaque by design. He launched Cost Plus Drugs in 2022 to pull back the curtain on drug pricing, bring down costs to the average consumer, and disrupt the traditional pharmacy industry. https://t.co/eYv7yZCtpp ...

Pharmaceutical Industry Pressure - Faith-based activists pressured Costco regarding mifepristone availability [1] - The group is now targeting CVS and Walgreens [1] Abortion Pill (Mifepristone) - Activists are specifically concerned about the abortion pill mifepristone [1] Retail Pharmacy Implications - Pharmacies like Costco, CVS, and Walgreens are facing pressure related to abortion pill offerings [1]

Industry Pressure - Faith-based activists pressured Costco to not offer mifepristone in its pharmacy locations [1] - The group is now focusing on CVS and Walgreens [1]

Industry Pressure - Faith-based activists previously pressured Costco regarding the abortion pill mifepristone [1] - The group is now focusing on CVS and Walgreens [1]

Pharmaceutical Industry & Social Activism - Faith-based activists pressured Costco to not offer mifepristone (abortion pill) in its pharmacies [1] - The activist group is now focusing on CVS and Walgreens regarding the abortion pill mifepristone [1]

A coalition of faith-based activists had pressured Costco to not offer the abortion pill mifepristone in its pharmacy locations. The group now turns its focus to CVS and Walgreens https://t.co/onQcBjz7pU ...

Wall Street banks including JPMorgan and UBS have begun early pricing discussions with investors for a $4.25 billion debt package to help finance Sycamore Partners' buyout of UK pharmacy Boots https://t.co/VpQzXN9Bdq ...

Market Dynamics & Competitive Landscape - CVS, through its PBM (Pharmacy Benefit Manager), is preferring Wegovy over Zepbound (Lilly) due to interchangeability and leveraging its coverage of millions of lives to negotiate better economic deals [1][3] - Lilly downplays the impact, stating only about 200,000 patients will be affected [5] - The shift is happening because drugs like Wegovy and Zepbound cost about $1,000 per month [3] PBM Strategy & Negotiation - PBMs negotiate drug prices in bulk, covering potentially tens of millions of lives, to bring prices down [4][5] - The prices are confidential, but some discount is surely involved [4] - Pharmacy benefits managers negotiate prices in bulk for millions of people [4] Patient Impact & Access - Patients have been scrambling to refill prescriptions, potentially seeking 90-day supplies, due to the change [6] - Patients are trying to determine if they are still covered, can get the drug at a discounted price, or qualify for a medical exemption [6]